retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Lilly's triple agonist, retatrutide, successful

This position alone can reduce straining by up to 50% according to research published in the Journal of Clinical Gastroenterology

Mounjaro represents the current gold standard in prescription obesity medications

In preclinical cellular models, the triple-receptor engagement profile of Retatrutide has been associated with modulation of AMP-activated protein kinase (AMPK) activity, alterations in fatty acid oxidation gene expression, and changes in hepatic glucose output markersthough the precise mechanistic contributions of each receptor axis remain an active area of investigation

Over the counter antihistamines like diphenhydramine (Benadryl) or cetirizine (Zyrtec) can reduce itching and minor allergic type reactions at injection sites